Abstract
The objectives of this study are to investigate allele frequencies of drug absorption, distribution, metabolism and elimination (ADME)-related genes in the Thai population and to compare these genes to HapMap populations including Caucasians (CEU), Africans (YRI) and Asians (CHB/JPT). Genetic variations of drug ADME-related genes in 190 Thais were investigated using drug metabolizing enzymes and transporters (DMET) plus genotyping system. We examined 1936 single nucleotide polymorphisms (SNPs) of 225 genes that have documented functional and clinical significances in phase I and phase II drug metabolism enzymes, drug transporters and other genes involved in ADME processes. Distributions of genotyping data from Thai were compared with other HapMap populations including Caucasian, African and Asian populations. The analysis demonstrated 43 SNPs with statistical significance comparing among five populations. However, only 26 SNPs showed statistical significance in pair-wise comparisons between Thai versus CEU and Thai versus CHB/JPT. These 26 SNPs belong to 13 groups of drug ADME-related genes which are CYP2A6, CYP3A5, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, VKORC1, COMT, NAT2, TPMT, UGT1A1 and SLCO1B1. These genes demonstrated clinical significances as previously observed in many studies. The results could explain clinical variability in pharmacokinetics and pharmacodynamics of drugs in Thais based on genetic variations in drug ADME-related gene emphasized in this article.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Fernandez, C. A., Smith, C., Yang, W., Lorier, R., Crews, K. R., Kornegay, N. et al. Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin. Pharmacol. Ther. 92, 360–365 (2012).
Rosenberg, N. A., Pritchard, J. K., Weber, J. L., Cann, H. M., Kidd, K. K., Zhivotovsky, L. A. et al. Genetic structure of human populations. Science 298, 2381–2385 (2002).
Wang, L., McLeod, H. L. & Weinshilboum, R. M. Genomics and drug response. N. Engl. J. Med. 364, 1144–1153 (2011).
Aekplakorn, W., Sangthong, R., Kessomboon, P., Putwatana, P., Inthawong, R., Taneepanichskul, S. et al. Changes in prevalence, awareness, treatment and control of hypertension in Thai population, 2004-2009: Thai National Health Examination Survey III-IV. J. Hypertens. 30, 1734–1742 (2012).
Burmester, J. K., Sedova, M., Shapero, M. H. & Mansfield, E. DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol. Biol. 632, 99–124 (2010).
Tassaneeyakul, W., Mahatthanatrakul, W., Niwatananun, K., Na-Bangchang, K., Tawalee, A., Krikreangsak, N. et al. CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab. Pharmacokinet. 21, 286–290 (2006).
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Meneveau, N. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363–375 (2009).
Wilkinson, G. R. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352, 2211–2221 (2005).
Suwannasri, P., Thongnoppakhun, W., Pramyothin, P., Assawamakin, A. & Limwongse, C. Combination of multiplex PCR and DHPLC-based strategy for CYP2D6 genotyping scheme in Thais. Clin. Biochem. 44, 1144–1152 (2011).
Sachse, C., Brockmoller, J., Bauer, S. & Roots, I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284–295 (1997).
Qin, S., Shen, L., Zhang, A., Xie, J., Shen, W., Chen, L. et al. Systematic polymorphism analysis of the CYP2D6 gene in four different geographical Han populations in mainland China. Genomics 92, 152–158 (2008).
Mannheimer, B., Wettermark, B., Lundberg, M., Pettersson, H., von Bahr, C. & Eliasson, E. Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions. Br. J. Clin. Pharmacol. 69, 411–417 (2010).
Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z. Y., Kaminsky, L. S., Shenfield, G. M. et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6, 341–349 (1996).
Bae, J. W., Kim, H. K., Kim, J. H., Yang, S. I., Kim, M. J., Jang, C. G. et al. Allele and genotype frequencies of CYP2C9 in a Korean population. Br. J. Clin. Pharmacol. 60, 418–422 (2005).
Kuanprasert, S., Dettrairat, S., Palacajornsuk, P., Kunachiwa, W. & Phrommintikul, A. Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand. J. Med. Assoc. Thai. 92, 1597–1601 (2009).
Limdi, N. A., Wadelius, M., Cavallari, L., Eriksson, N., Crawford, D. C., Lee, M. T. et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115, 3827–3834 (2010).
Sangviroon, A., Panomvana, D., Tassaneeyakul, W. & Namchaisiri, J. Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin. Drug Metab. Pharmacokinet. 25, 531–538 (2010).
Roy, J. N., Lajoie, J., Zijenah, L. S., Barama, A., Poirier, C., Ward, B. J. et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab. Dispos. 33, 884–887 (2005).
Zhu, H. J., Yuan, S. H., Fang, Y., Sun, X. Z., Kong, H. & Ge, W. H. The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis. Pharmacogenomics J. 11, 237–246 (2011).
Kukongviriyapan, V., Prawan, A., Tassaneyakul, W., Aiemsa-Ard, J. & Warasiha, B. Arylamine N-acetyltransferase-2 genotypes in the Thai population. Br. J. Clin. Pharmacol. 55, 278–281 (2003).
Higuchi, N., Tahara, N., Yanagihara, K., Fukushima, K., Suyama, N., Inoue, Y. et al. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J. Gastroenterol. 13, 6003–6008 (2007).
He, J., Qiu, Z., Li, N., Yu, Y., Lu, Y., Han, D. et al. Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. Eur. J. Clin. Pharmacol. 67, 701–707 (2011).
Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F. et al. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N. Engl. J. Med. 359, 789–799 (2008).
Di, Y. M., Chow, V. D., Yang, L. P. & Zhou, S. F. Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr. Drug Metab. 10, 754–780 (2009).
Zanger, U. M., Klein, K., Saussele, T., Blievernicht, J., Hofmann, M. H. & Schwab, M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8, 743–759 (2007).
Daily, E. B. & Aquilante, C. L. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 10, 1489–1510 (2009).
Higashi, M. K., Veenstra, D. L., Kondo, L. M., Wittkowsky, A. K., Srinouanprachanh, S. L., Farin, F. M. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690–1698 (2002).
Li-Wan-Po, A., Girard, T., Farndon, P., Cooley, C. & Lithgow, J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br. J. Clin. Pharmacol. 69, 222–230 (2010).
McAlpine, D. E., Biernacka, J. M., Mrazek, D. A., O'Kane, D. J., Stevens, S. R., Langman, L. J. et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther. Drug Monit. 33, 14–20 (2011).
Ross, K. A., Bigham, A. W., Edwards, M., Gozdzik, A., Suarez-Kurtz, G. & Parra, E. J. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J. Hum. Genet. 55, 582–589 (2010).
Klepstad, P., Dale, O., Skorpen, F., Borchgrevink, P. C. & Kaasa, S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol. Scand. 49, 902–908 (2005).
Chamorro, J. G., Castagnino, J. P., Musella, R. M., Nogueras, M., Aranda, F. M., Frias, A. et al. Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J. Gastroenterol. Hepatol. 28, 323–328 (2013).
Krynetski, E. Y., Schuetz, J. D., Galpin, A. J., Pui, C. H., Relling, M. V. & Evans, W. E. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Natl Acad. Sci. USA 92, 949–953 (1995).
Sugatani, J. Function, genetic polymorphism, and transcriptional regulation of human UDP-glucuronosyltransferase (UGT) 1A1. Drug Metab. Pharmacokinet. 28, 83–92 (2013).
Gerloff, T., Schaefer, M., Mwinyi, J., Johne, A., Sudhop, T., Lutjohann, D. et al. Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels. Naunyn Schmiedebergs Arch. Pharmacol. 373, 45–50 (2006).
Acknowledgements
This project was financially supported by the Pharmacogenomics Project under collaboration between Ramathibodi Hospital and Thailand Center of Excellence for Life Sciences as well as UNC Institute for Pharmacogenomics and Individualized Therapy. The DNA samples were kindly provided by Department of Medical Sciences, Ministry of Public Health and Health System Research Institute.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on Journal of Human Genetics website
Supplementary information
Rights and permissions
About this article
Cite this article
Jittikoon, J., Mahasirimongkol, S., Charoenyingwattana, A. et al. Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations. J Hum Genet 61, 119–127 (2016). https://doi.org/10.1038/jhg.2015.115
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/jhg.2015.115
This article is cited by
-
A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy
The Pharmacogenomics Journal (2021)
-
Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation
The Pharmacogenomics Journal (2020)
-
Polymorphisms of ADME-related genes and their implications for drug safety and efficacy in Amazonian Amerindians
Scientific Reports (2019)
-
Exploring Variation in Known Pharmacogenetic Variants and its Association with Drug Response in Different Mexican Populations
Pharmaceutical Research (2016)
